{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T19:32:53Z","timestamp":1774035173647,"version":"3.50.1"},"reference-count":39,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15366","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:16:42Z","timestamp":1761830202000},"page":"1-10","source":"Crossref","is-referenced-by-count":1,"title":["Sensitive cell\u2011free DNA assay for accurate detection of RAS and BRAF mutations in liquid biopsies of patients with metastatic colorectal cancer: Final results of the multicentric ColoBEAM study"],"prefix":"10.3892","volume":"31","author":[{"given":"Alexandre","family":"Harl\u00e9","sequence":"first","affiliation":[{"name":"D\u00e9partement de Biopathologie, Institut de Canc\u00e9rologie de Lorraine, CNRS UMR 7039 CRAN, Universit\u00e9 de Lorraine, 54519 Vandoeuvre\u2011L\u00e8s\u2011Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Gavoille","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut de Canc\u00e9rologie de Lorraine, 54519 Vand\u0153uvre\u2011l\u00e8s\u2011Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[{"name":"Department of Digestive Oncology, CHU Reims, Universit\u00e9 de Reims Champagne Ardenne, 51000 Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meher","family":"Abdelghani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Paul Strauss, 67000 Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9rome","family":"Plaza","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, H\u00f4pitaux Priv\u00e9s de Metz, 57000 Metz, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Spaeth","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Polyclinique de Gentilly, 54000 Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axelle","family":"Boudrant","sequence":"additional","affiliation":[{"name":"Department of Oncology, William Morey Hospital, 71000 Chalon\u2011sur\u2011Sa\u00f4ne, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Ghiringhelli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Georges\u2011Francois Leclerc, 21000 Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Laure","family":"Villing","sequence":"additional","affiliation":[{"name":"Department of Oncology, Auxerre Hospital, Auxerre 88000, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Borg","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Hospitalier Universitaire Jean Minjoz, 25000 Besan\u00e7on, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Rouyer","sequence":"additional","affiliation":[{"name":"Institut de Canc\u00e9rologie de Lorraine, D\u00e9partement de Biopathologie, 54519 Vand\u0153uvre\u2011l\u00e8s\u2011Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Husson","sequence":"additional","affiliation":[{"name":"Institut de Canc\u00e9rologie de Lorraine, D\u00e9partement de Biopathologie, 54519 Vand\u0153uvre\u2011l\u00e8s\u2011Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Gilson","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biopathologie, Institut de Canc\u00e9rologie de Lorraine, CNRS UMR 7039 CRAN, Universit\u00e9 de Lorraine, 54519 Vandoeuvre\u2011L\u00e8s\u2011Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Salleron","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Institut de Canc\u00e9rologie de Lorraine, 54519 Vand\u0153uvre\u2011l\u00e8s\u2011Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lien","family":"Lambert","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut de Canc\u00e9rologie de Lorraine, 54519 Vand\u0153uvre\u2011l\u00e8s\u2011Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Merlin","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biopathologie, Institut de Canc\u00e9rologie de Lorraine, CNRS UMR 7039 CRAN, Universit\u00e9 de Lorraine, 54519 Vandoeuvre\u2011L\u00e8s\u2011Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"key20251205105254_b1-ol-31-1-15366","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"key20251205105254_b2-ol-31-1-15366","first-page":"233","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"key20251205105254_b3-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ejca.2021.07.039","article-title":"The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers","volume":"157","author":"Dyba","year":"2021","journal-title":"Eur J Cancer"},{"key":"key20251205105254_b4-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"key20251205105254_b5-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib Plus Cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20251205105254_b6-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13046-023-02743-9","article-title":"Network approach in liquidomics landscape","volume":"42","author":"Santini","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"key20251205105254_b7-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.dld.2017.12.029","article-title":"RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014","volume":"50","author":"Li\u00e8vre","year":"2018","journal-title":"Dig Liver Dis"},{"key":"key20251205105254_b8-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13046-018-0723-5","article-title":"Monitoring the effect of first line treatment in RAS\/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma","volume":"37","author":"Thomsen","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"key20251205105254_b9-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13046-020-01569-z","article-title":"Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy","volume":"39","author":"Allegretti","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"key20251205105254_b10-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1373\/clinchem.2013.206359","article-title":"Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients","volume":"59","author":"Taly","year":"2013","journal-title":"Clin Chem"},{"key":"key20251205105254_b11-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nm.3511","article-title":"Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA","volume":"20","author":"Thierry","year":"2014","journal-title":"Nat Med"},{"key":"key20251205105254_b12-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Van Cutsem","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20251205105254_b13-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study","volume":"22","author":"Bokemeyer","year":"2011","journal-title":"Ann Oncol"},{"key":"key20251205105254_b14-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20251205105254_b15-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"key20251205105254_b16-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"e0227294","DOI":"10.1371\/journal.pone.0227294","article-title":"Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer","volume":"15","author":"Franczak","year":"2020","journal-title":"PLoS One"},{"key":"key20251205105254_b17-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"e0212801","DOI":"10.1371\/journal.pone.0212801","article-title":"Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma","volume":"14","author":"Franczak","year":"2019","journal-title":"PLoS One"},{"key":"key20251205105254_b18-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s10238-023-01278-9","article-title":"Tumor-derived cell-free DNA and circulating tumor cells: Partners or rivals in metastasis formation?","volume":"24","author":"Witz","year":"2024","journal-title":"Clin Exp Med"},{"key":"key20251205105254_b19-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"key20251205105254_b20-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20251205105254_b21-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/s41416-018-0293-5","article-title":"Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer","volume":"119","author":"Garc\u00eda-Foncillas","year":"2018","journal-title":"Br J Cancer"},{"key":"key20251205105254_b22-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"101718","DOI":"10.1016\/j.tranon.2023.101718","article-title":"A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer","volume":"35","author":"Osumi","year":"2023","journal-title":"Transl Oncol"},{"key":"key20251205105254_b23-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"key20251205105254_b24-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1093\/annonc\/mdx330","article-title":"Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment","volume":"28","author":"Thierry","year":"2017","journal-title":"Ann Oncol"},{"key":"key20251205105254_b25-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"8976","DOI":"10.1038\/s41598-019-45616-y","article-title":"Comparison of the clinical sensitivity of the Idylla platform and the OncoBEAM RAS CRC assay for KRAS Mutation detection in liquid biopsy samples","volume":"9","author":"Vivancos","year":"2019","journal-title":"Sci Rep"},{"key":"key20251205105254_b26-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/annonc\/mdx112","article-title":"Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer","volume":"28","author":"Grasselli","year":"2017","journal-title":"Ann Oncol"},{"key":"key20251205105254_b27-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/annonc\/mdx125","article-title":"Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients","volume":"28","author":"Vidal","year":"2017","journal-title":"Ann Oncol"},{"key":"key20251205105254_b28-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41416-019-0457-y","article-title":"A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer","volume":"120","author":"Bando","year":"2019","journal-title":"Br J Cancer"},{"key":"key20251205105254_b29-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1200\/PO.20.00117","article-title":"Rising circulating tumor DNA as a molecular biomarker of early disease progression in metastatic breast cancer","volume":"4","author":"Velimirovic","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"key20251205105254_b30-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41416-022-01769-8","article-title":"Liquid biopsies to monitor and direct cancer treatment in colorectal cancer","volume":"127","author":"Mauri","year":"2022","journal-title":"Br J Cancer"},{"key":"key20251205105254_b31-ol-31-1-15366","article-title":"Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases","volume":"5","author":"Loupakis","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"key20251205105254_b32-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"key20251205105254_b33-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: A clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann Oncol"},{"key":"key20251205105254_b34-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"key20251205105254_b35-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"key20251205105254_b36-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1111\/cas.14926","article-title":"CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer","volume":"112","author":"Taniguchi","year":"2021","journal-title":"Cancer Sci"},{"key":"key20251205105254_b37-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"key20251205105254_b38-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"key20251205105254_b39-ol-31-1-15366","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T08:53:04Z","timestamp":1764924784000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,30]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15366","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}